0K30 Stock Overview
A clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
TFF Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.18 |
| 52 Week High | €8.00 |
| 52 Week Low | €1.42 |
| Beta | 1.06 |
| 1 Month Change | 0% |
| 3 Month Change | 21.79% |
| 1 Year Change | -53.27% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0K30 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 1.9% |
| 1Y | -53.3% | -9.1% | 14.1% |
Return vs Industry: 0K30 underperformed the German Pharmaceuticals industry which returned -13.4% over the past year.
Return vs Market: 0K30 underperformed the German Market which returned 12.6% over the past year.
Price Volatility
| 0K30 volatility | |
|---|---|
| 0K30 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 0K30's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 0K30's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 19 | Craig Jalbert | tffpharma.com |
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company’s drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection.
TFF Pharmaceuticals, Inc. Fundamentals Summary
| 0K30 fundamental statistics | |
|---|---|
| Market cap | €9.69m |
| Earnings (TTM) | -€17.66m |
| Revenue (TTM) | €1.11m |
8.8x
P/S Ratio-0.5x
P/E RatioIs 0K30 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0K30 income statement (TTM) | |
|---|---|
| Revenue | US$1.16m |
| Cost of Revenue | US$10.70m |
| Gross Profit | -US$9.54m |
| Other Expenses | US$8.98m |
| Earnings | -US$18.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.17 |
| Gross Margin | -821.41% |
| Net Profit Margin | -1,595.04% |
| Debt/Equity Ratio | 0% |
How did 0K30 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/28 18:47 |
| End of Day Share Price | 2024/10/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TFF Pharmaceuticals, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |